

Approval and implementation dates for specific health plans may vary. Please consult the applicable health plan for more details.

Clinical Appropriateness Guidelines

Genetic Testing

Appropriate Use Criteria: Prenatal Screening using Cell- free DNA

Proprietary

© 2026 Carelon Medical Benefits Management, Inc. All rights reserved.

Table of Contents

| | |
|---------------------------------------------------------------------------------|----|
| Description and Application of the Guidelines | 3 |
| General Clinical Guideline | 4 |
| Clinical Appropriateness Framework | 4 |
| Simultaneous Ordering of Multiple Diagnostic or Therapeutic Interventions | 4 |
| Repeat Diagnostic Intervention | 4 |
| Repeat Therapeutic Intervention | 5 |
| Prenatal Screening using Cell-free DNA | 6 |
| Description and Scope | 6 |
| General Recommendations | 6 |
| Clinical Indications | 7 |
| General Requirements | 7 |
| Condition-Specific Requirements | 7 |
| References | 10 |
| Codes | 11 |
| History | 12 |

Description and Application of the Guidelines

The Carelon Clinical Appropriateness Guidelines (hereinafter “the Carelon Clinical Appropriateness Guidelines” or the “Guidelines”) are designed to assist providers in making the most appropriate treatment decision for a specific clinical condition for an individual. The Guidelines establish objective and evidence-based criteria for medical necessity determinations, where possible, that can be used in support of the following:

- To establish criteria for when services are medically necessary
- To assist the practitioner as an educational tool
- To encourage standardization of medical practice patterns
- To curtail the performance of inappropriate and/or duplicate services
- To address patient safety concerns
- To enhance the quality of health care
- To promote the most efficient and cost-effective use of services

The Carelon guideline development process complies with applicable accreditation and legal standards, including the requirement that the Guidelines be developed with involvement from appropriate providers with current clinical expertise relevant to the Guidelines under review and be based on the most up-to-date clinical principles and best practices. Resources reviewed include widely used treatment guidelines, randomized controlled trials or prospective cohort studies, and large systematic reviews or meta-analyses. Carelon reviews all of its Guidelines at least annually.

Carelon makes its Guidelines publicly available on its website. Copies of the Guidelines are also available upon oral or written request. Additional details, such as summaries of evidence, a list of the sources of evidence, and an explanation of the rationale that supports the adoption of the Guidelines, are included in each guideline document.

Although the Guidelines are publicly available, Carelon considers the Guidelines to be important, proprietary information of Carelon, which cannot be sold, assigned, leased, licensed, reproduced or distributed without the written consent of Carelon.

Carelon applies objective and evidence-based criteria, and takes individual circumstances and the local delivery system into account when determining the medical appropriateness of health care services. The Carelon Guidelines are just guidelines for the provision of specialty health services. These criteria are designed to guide both providers and reviewers to the most appropriate services based on a patient’s unique circumstances. In all cases, clinical judgment consistent with the standards of good medical practice should be used when applying the Guidelines. Guideline determinations are made based on the information provided at the time of the request. It is expected that medical necessity decisions may change as new information is provided or based on unique aspects of the patient’s condition. The treating clinician has final authority and responsibility for treatment decisions regarding the care of the patient and for justifying and demonstrating the existence of medical necessity for the requested service. The Guidelines are not a substitute for the experience and judgment of a physician or other health care professionals. Any clinician seeking to apply or consult the Guidelines is expected to use independent medical judgment in the context of individual clinical circumstances to determine any patient’s care or treatment.

The Guidelines do not address coverage, benefit or other plan specific issues. Applicable federal and state coverage mandates take precedence over these clinical guidelines, and in the case of reviews for Medicare Advantage Plans, the Guidelines are only applied where there are not fully established CMS criteria. If requested by a health plan, Carelon will review requests based on health plan medical policy/guidelines in lieu of the Carelon Guidelines. Use of an FDA-approved or conditionally approved product does not constitute medical necessity or guarantee reimbursement by the respective health plan.

The Guidelines may also be used by the health plan or by Carelon for purposes of provider education, or to review the medical necessity of services by any provider who has been notified of the need for medical necessity review, due to billing practices or claims that are not consistent with other providers in terms of frequency or some other manner.

General Clinical Guideline

Clinical Appropriateness Framework

Critical to any finding of clinical appropriateness under the guidelines for a specific diagnostic or therapeutic intervention are the following elements:

- Prior to any intervention, it is essential that the clinician confirm the diagnosis or establish its pretest likelihood based on a complete evaluation of the patient. This includes a history and physical examination and, where applicable, a review of relevant laboratory studies, diagnostic testing, and response to prior therapeutic intervention.
- The anticipated benefit of the recommended intervention is likely to outweigh any potential harms, including from delay or decreased access to services that may result (net benefit).
- Widely used treatment guidelines and/or current clinical literature and/or standards of medical practice should support that the recommended intervention offers the greatest net benefit among competing alternatives.
- There exists a reasonable likelihood that the intervention will change management and/or lead to an improved outcome for the patient.

Providers may be required to submit clinical documentation in support of a request for services. Such documentation must a) accurately reflect the clinical situation at the time of the requested service, and b) sufficiently document the ordering provider's clinical intent.

If these elements are not established with respect to a given request, the determination of appropriateness will most likely require a peer-to-peer conversation to understand the individual and unique facts that would justify a finding of clinical appropriateness. During the peer-to-peer conversation, factors such as patient acuity and setting of service may also be taken into account to the extent permitted by law.

Genetic tests not specifically mentioned in the guidelines are considered not medically necessary.

Simultaneous Ordering of Multiple Diagnostic or Therapeutic Interventions

Requests for multiple diagnostic or therapeutic interventions at the same time will often require a peer-to-peer conversation to understand the individual circumstances that support the medical necessity of performing all interventions simultaneously. This is based on the fact that appropriateness of additional intervention is often dependent on the outcome of the initial intervention.

Additionally, either of the following may apply:

- Current literature and/or standards of medical practice support that one of the requested diagnostic or therapeutic interventions is more appropriate in the clinical situation presented; or
- One of the diagnostic or therapeutic interventions requested is more likely to improve patient outcomes based on current literature and/or standards of medical practice.

Repeat Diagnostic Intervention

In general, repeated testing of the same anatomic location for the same indication should be limited to evaluation following an intervention, or when there is a change in clinical status such that additional testing is required to determine next steps in management. At times, it may be necessary to repeat a test using different techniques or protocols to clarify a finding or result of the original study.

Repeated testing for the same indication using the same or similar technology may be subject to additional review or require peer-to-peer conversation in the following scenarios:

- Repeated diagnostic testing at the same facility due to technical issues

- Repeated diagnostic testing requested at a different facility due to provider preference or quality concerns
- Repeated diagnostic testing of the same anatomic area based on persistent symptoms with no clinical change, treatment, or intervention since the previous study
- Repeated diagnostic testing of the same anatomic area by different providers for the same member over a short period of time

Repeat Therapeutic Intervention

In general, repeated therapeutic intervention in the same anatomic area is considered appropriate when the prior intervention proved effective or beneficial and the expected duration of relief has lapsed. A repeat intervention requested prior to the expected duration of relief is not appropriate unless it can be confirmed that the prior intervention was never administered. Requests for ongoing services may depend on completion of previously authorized services in situations where a patient's response to authorized services is relevant to a determination of clinical appropriateness.

Prenatal Screening using Cell-free DNA

Description and Scope

Cell-free DNA (cfDNA) screening for aneuploidy, sometimes called noninvasive prenatal screening (NIPS) or noninvasive prenatal testing (NIPT), evaluates DNA from the placenta in the maternal circulation to screen for specific chromosomal abnormalities, known as aneuploidies, in the pregnancy.

These tests can identify pregnancies at increased risk for these conditions but cannot definitively diagnose, confirm, or exclude them. Screening tests that show increased risk should be confirmed by diagnostic testing prior to any intervention.

For testing associated with reproduction, see the Carelon Guidelines [Carrier Screening in the Reproductive Setting](#).

General Recommendations

Genetic counseling

The approach chosen for any prenatal screening technique should involve shared decision-making between the patient and the clinician. Counseling is encouraged prior to any prenatal screening that involves cell-free DNA and should include **ALL** of the following components:

- Clearly defined differences between screening and diagnostic prenatal genetic testing
- Risk assessment for and education about aneuploidies
- Counseling to promote informed choices and adaptation to the risk or presence of a genetic condition
- Counseling for the psychological aspects of genetic testing

Note: Post-test counseling should be performed for any positive or non-reportable cfDNA screen result.

Rationale

As stated above, it should be stressed that this specific type of testing is a screening modality, as opposed to a diagnostic one. Additionally, the approach chosen for any prenatal screening technique should involve shared decision-making between the patient and the clinical team. Like any other genetic screening test, cell-free DNA testing is a process that involves risk that accompanies its potential benefits and, therefore, the clinical team and the patient should consider the balance of risks and potential benefits before testing is pursued through informed consent. Furthermore, the clinical utility of a genetic screening test must be considered along with its psychological and sociological implications.¹ Counseling, either by a genetic counselor and/or team clinician, provides a patient-centered approach to the care of individuals who are undergoing a genetic screening test, such as prenatal testing.

It is also recognized that accessibility to genetic counselors is limited by available resources as well as other social determinants of health. Therefore, as it relates to screening, the importance should be placed on counseling in a general sense, such as informed consent, as noted above.

As with any genetic test, whether for screening or diagnosis, genomic technologies generate large amounts of data, and this increases the potential for uncertainty in managing and adapting to this information. The clinical team is tasked with accurately interpreting and communicating information about test validity and the reliability of test results, as well as the probability for individual patient benefit.² Uncovering incidental findings and being overwhelmed with information are important possible consequences to genetic testing, particularly among vulnerable patient subgroups.³ Counseling is an invaluable resource for patients undergoing genetic screening testing, but there are practical limitations because of the scarcity of resources relative to the current need, as noted above.

Clinical Indications

General Requirements

Prenatal screening using cell-free DNA (cfDNA) should occur only once per fetus per pregnancy.

Condition-Specific Requirements

Viable singleton or twin pregnancy

Prenatal screening using cell-free DNA (cfDNA) is considered **medically necessary** in viable singleton or twin pregnancies at 9 weeks gestation or later for aneuploidies of the following chromosomes:

- 13
- 18
- 21
- X
- Y

This includes the following indications:

- As follow-up to abnormal maternal serum screen results when diagnostic testing is declined
- Pregnancies with multiple anomalies **AND** diagnostic testing is not possible

Not Medically Necessary:

The use of cfDNA screening is considered **not medically necessary** for clinical scenarios including, but not limited to, the following:

- Higher order gestations (≥ 3 fetuses)
- Fetal demise
- Co-twin demise (vanishing twin)
- Multiple fetal anomalies
- Concurrent screening with other maternal serum biomarkers
- Prior to 9 weeks gestation

The use of cfDNA screening is considered **not medically necessary** when screening for the following:

- Sex only (without family history of an X-linked disorder)
- Single genes (e.g., CFTR, HBB, SMN1, RhD and/or other fetal red blood cell antigens)
- Microdeletions (e.g., DiGeorge syndrome, Cri-du-chat syndrome)
- Twin zygosity (monozygotic versus dizygotic)
- Genome-wide copy number variants
- Aneuploidies of other autosomal chromosomes (e.g., trisomy 7, trisomy 15, trisomy 16, trisomy 22, etc.)
- Polygenic risk assessment

Note: Some of the tests listed above have a role in care under certain circumstances, but they should not be routinely offered.

Rationale

Chromosomal abnormalities (aneuploidy, translocations, duplication, or deletions) are present in approximately 1 in 150 live births, with 3% to 5% of pregnancies ultimately complicated by birth defects or genetic disorders.⁴ For various reasons, some patients choose to pursue screening for underlying genetic disorders with decisions about such testing and possible subsequent actions being driven heavily by patient values. Various screening techniques are available, and the field is rapidly evolving. Techniques in the first trimester include serum screening using markers (such as beta human chorionic gonadotropin, alpha-fetoprotein, inhibin A, and unconjugated estriol), and ultrasound testing to assess nuchal translucency. Integrated screening techniques produce a detection rate of about 96% with around 5% false positives.⁴

Over the past 12 years, the rapid advances in genomic medicine have brought new technology into use for prenatal screening. Cell-free DNA (cfDNA) screening refers to sequence analysis of placental cfDNA fragments that circulate in the blood of pregnant women, along with the translation of this method into screening for chromosome abnormalities. Approaches for cfDNA include shotgun whole genome and targeted sequencing.⁵ The shotgun approach of whole genome sequencing generates short sequences from across the genome which are then aligned to a reference chromosome and counted. In contrast, targeted sequencing of the cfDNA is based on next-generation sequencing (NGS) and involves amplification of selected chromosomal loci on the chromosomes of interest.^{6,7} Of note, while cfDNA methods can detect chromosomal abnormalities in pregnancy, they do not assess the risk of fetal structural anomalies such as neural tube defects or ventral wall defects.⁶

Cell-free DNA was initially validated as a clinical prenatal screen for pregnancies at high risk for trisomy 21, and it has since been approved to determine fetal sex and screen for fetal aneuploidy, including trisomies 13 (Patau syndrome), 18 (Edward syndrome), and 21 (Down syndrome) in high-risk and average-risk pregnancies.⁶ At any given maternal age, the rate of common trisomies is similar between singleton and twin pregnancies, and cfDNA screening provides higher predictive values among twin pregnancies compared to traditional serum and nuchal translucency based techniques.⁸ A systematic evidence review evaluating cfDNA for screening in a general risk population found that it is the most effective screening approach for trisomies 13, 18, and 21 in singleton and twin gestations with both high detection and low false-positive rates.⁹ In addition, a systematic review and meta-analysis evaluating cfDNA screening in singleton pregnancies found that it reliably detects sex chromosome abnormalities (45,X, 47,XXY, 47,XXX and 47,XYY) with high sensitivity and specificity.¹⁰

Authors stress that false positives and false negatives exist with all prenatal cfDNA screens. Several professional societies and the U.S. Food and Drug Administration (FDA) endorse genetic counseling prior to and following prenatal screening to explore the conditions being screened, the patient's desire avidity for this information, follow-up logistics, decision-making options, and the significance of screening results.¹¹⁻¹⁴ Definitive diagnosis of abnormalities detected on screening requires sampling of pregnancy tissue by chorionic villous sampling or amniocentesis for chromosomal array analysis.⁶ These diagnostic tests are associated with some risk of miscarriage.

The position of the American College of Obstetrics and Gynecology (ACOG) and the Society for Maternal-Fetal Medicine (SMFM) in 2020 was that "prenatal genetic screening (serum screening with or without nuchal translucency ultrasound or cell-free DNA screening) and diagnostic testing (chorionic villus sampling [CVS] or amniocentesis) options should be discussed and offered to all pregnant women regardless of maternal age or risk of chromosomal abnormality. After review and discussion, every patient has the right to pursue or decline prenatal genetic screening and diagnostic testing."¹¹ The American College of Medical Genetics and Genomics (ACMG) position has been favorable toward offering women the option of cfDNA screening since 2016, ultimately recommending that patients receive accurate and balanced information to promote patient-centered, nondirective decision-making.¹⁵ In 2020, ACMG recommended informing all pregnant women that cfDNA screening is the most sensitive screening option for common aneuploidies, did not recommend maternal age or risk of chromosomal abnormality as a basis to choose between aneuploidy testing approaches, and did not recommend having multiple screening methods performed simultaneously.¹⁶ In a 2023 ACMG Practice Guideline published based on a systematic evidence review, ACMG strongly recommends cfDNA screening over traditional screening methods for all pregnant patients with singleton and twin gestations for fetal trisomies 21, 18, and 13. They also strongly recommend cfDNA screening be offered to individuals with a singleton gestation to screen for fetal sex chromosome abnormalities (monosomy X, XXX, XXY, and XYY) based on a high certainty of evidence.¹² This same ACMG Practice Guideline uses weaker language to *conditionally suggest* that cfDNA screening for 22q11.2 deletion syndrome be offered to all patients, based on a *moderate certainty of the evidence*; however, ACMG's systematic evidence review demonstrated that the sensitivity and specificity of copy number variant screening are below that of the common trisomies and sex chromosome abnormalities.¹² In addition, the 2023 International Society for Prenatal Diagnosis (ISPD) Position Statement affirms there is insufficient data to assess the performance and clinical utility of routine cfDNA screening for microdeletion/microduplications syndromes including 22q11.2 deletion syndrome, and cfDNA screening for microdeletion/microduplications syndromes is not recommended for the routine care of unselected populations.¹³ Furthermore, while cfDNA screening is not regulated by the FDA, an FDA Safety Communication was released in 2022 regarding false positive results with cfDNA screening. Specifically, the FDA stated that the ability of a cfDNA screening test to

determine fetal risk of a genetic abnormality depends on the pregnancy's *a priori* risk. Because the prevalence of microdeletions is low in an average-risk population, the chance of receiving a false positive result is higher.¹⁴

A retrospective analysis of over 70,000 pregnancies in a single center using a single lab and testing platform focused on the use of genome-wide cfDNA screening to include common trisomies, sex chromosome aneuploidies (SCAs), rare autosomal trisomies, copy number variants (at least 7 Mb), and microdeletions.¹⁷ While performance for trisomies 13, 18, 21 and the SCAs was high, as expected, the overall smaller numbers of positive results, higher false positive rates, and lower positive predictive values for each of the remaining potential abnormalities did not provide robust evidence of clinical utility. The second study, sponsored by Myriad Genetics, focused attention on improving the detection of the 22q11.2 microdeletion. Both high-risk and average-risk indications for testing were included.¹⁸ Of nearly 380,000 samples analyzed, 76 (0.02%) were screen-positive for the deletion. There was incomplete follow-up for these pregnancies; slightly < 30% (22/76) had confirmatory prenatal diagnostic testing, the majority with ultrasound findings suggestive of the syndrome. The authors were unable to calculate sensitivity, specificity, or NPV from their data set and acknowledged that their calculated PPV was likely enriched by the higher uptake of diagnostic testing in the presence of suspicious ultrasound findings.

ACMG and ISPD both cite lack of sufficient data to assess the performance and clinical utility of routine cfDNA for rare autosomal trisomies (RATs) as rationale for providing no recommendation or not recommending screening for RATs in the routine care of unselected populations,¹³ respectively. Lastly, noninvasive prenatal screening for single-gene disorders is not widespread in clinical practice because of the low prevalence of diseases, the complexity of the testing methods, and the chance of a no-call result in a high-risk pregnancy.¹⁹

Clinical and laboratory attention has turned to more routine use of cfDNA screening to predict fetal genotype for selected red blood cell antigens. Although there are more than 50 red blood cell antigens known, the two primary blood groups in humans are ABO and Rh which determine blood type and Rh status, respectively. These specific genotypes are important in the field of obstetrics as well as in transfusion medicine. The risk to develop hemolytic disease of the fetus and newborn (HDFN), a condition associated with fetal anemia and a higher likelihood of perinatal death, is increased among those pregnancies where Rh incompatibility exists between the pregnant individual and the fetus. The most common Rh antigens are D, C, c, E, and e. The D antigen is encoded by one gene (*RHD*) while the C/c and E/e antigens are coded by a second, related gene (*RHCE*). An RhD-positive blood type is more common overall in the general population across all racial and ethnic groups. In the US, however, the frequency of those with RhD-negative blood varies with estimates of 15%-17% of all Whites, 7%-8% among Hispanics and Blacks, and 1%-2% in Asians.²⁰ At the molecular level, most individuals who are RhD-negative have a full deletion of the *RHD* gene. This is the most common, but not only, variant among Whites; a full deletion of *RHD* is less common in non-White populations.

Overall, it is currently estimated that < 1.0% of all pregnancies in the US are complicated by RhD alloimmunization. This is a significant decrease from the historic statistic of ~16% of pregnancies among RhD-negative individuals. The reduction is directly attributable to prophylactic administration of RhD immunoglobulin (RhIg) to those who are RhD-sensitized, a practice which began in many industrialized countries, including the US, in the late 1960s.²¹ The Society for Maternal-Fetal Medicine (SMFM) published a clinical guideline in 2015 outlining management recommendations for pregnancies determined to be at-risk for alloimmunization.²² These recommendations include genotyping of the biological father of the pregnancy as a first step. If he is determined to be RhD-negative, and paternity is certain, no additional follow-up, either in the prenatal or postnatal periods, is indicated. However, if he is determined to be RhD-positive, fetal testing to determine the RhD genotype is recommended. Diagnostic testing via amniocentesis is preferred over chorionic villus sampling (CVS) but SMFM also suggested that cfDNA screening for RhD status could be considered as an alternative to amniocentesis. For those individuals predicted to be carrying a RhD-negative fetus, prophylactic RhIg is typically administered at 26-28 weeks gestation and then again after delivery if the neonate is either known or newly confirmed to be RhD-negative. Additional antenatal prophylactic doses are recommended following other instances where sensitization may occur, including after first trimester bleeding, ectopic pregnancy, any blunt trauma, or post-amniocentesis or CVS.^{21, 22}

While the available data is promising, the clinical utility of cfDNA-based screening to determine predicted fetal red blood cell antigen genotype in a multicultural US population has not yet been firmly established. Two studies supported by the commercial genetic testing laboratory BillionToOne demonstrated high sensitivities and specificities for six red blood cell antigens including RhD.^{23, 24} Alford et al. used a set of twelve (12) preclinical sample sets (parent/child genomic DNA pairs) with known red blood cell antigen genotypes to initially create a simulated library of cfDNA. A total of 1,077 samples, across a range of fetal fractions (1.5%-12%) and antigens (e.g., D, C, c, E, K [Kell], and Fy^a) were analyzed. A total of sixteen (16) had no-call results, most because of too few fetal molecules. The fetal antigen in question was detected in 600 samples and not detected in 461 samples, leading to an overall sensitivity of 100% (95% CI: 99-100%) and specificity of 100% (95% CI: 99-100%). Follow-up using a total of 53 plasma samples from pregnant individuals with known fetal antigen status subsequently also showed high clinical sensitivity and specificity. The authors concluded that use of cfDNA for fetal antigen genotyping can significantly reduce the health care burden by not only reducing the prophylactic administration of RhIg to all RhD-negative patients but also by decreasing the need and cost associated with fetal monitoring for those pregnancies predicted to be low risk for HDFN. While no official cost analysis was completed as part of their work, the authors point to the European experience of routinely offering fetal RhD cfDNA screening as evidence of an improved standard of care. This, unfortunately,

bypasses some of the unique challenges of the European protocol, including testing delayed until at least 20 weeks gestation, a limited ability to detect all RhD variants and/or a high rate of inconclusive results in European non-White individuals with, consequently, a significant rate of repeat testing. Nonetheless, the authors additionally state that, in the US, the use of cfDNA for this purpose may be more effective in the identification of alloimmunized pregnancies than the current ACOG/SMFM guidelines given the ~10% rate of misattributed paternity as well as incomplete partner testing and/or low uptake of diagnostic testing.

Rego et al. further built upon this work by examining the concordance rates between a set of 156 parent/neonate pairs where both fetal antigen cfDNA and neonatal testing had been previously performed. The median gestational age at the time of cfDNA testing was 16.4 weeks with a median fetal fraction of 11.1%. The participants were majority White (65.4%). Neonatal testing, completed between DOL 0-270, was completed via buccal swab for antigens C, c, E, Kell, and Fy^a. Testing for the D antigen was completed via sequence analysis of the *RHD* gene. Thirty-four (34) of the pregnant patients showed alloimmunization to more than one (1) antigen. The authors report concordance for 190 alloimmunized antigen calls from 155 patients; one patient's results were excluded due to inconclusive neonatal *RHD* sequencing results. The limitations of the assay include exclusion of other red blood cell antigens known to cause HDFN, although it should be noted that the primary antigens associated with either high- or moderate-risk were included. The authors outline exclusions for fetal antigen cfDNA screening including in those pregnant individuals who have a history of either solid organ or bone marrow transplant, recent blood transfusion, or known malignancy. Pregnancies also complicated by a vanishing twin would not be good candidates for this approach. Like Alford et al., the authors concluded that the use of cfDNA for assessment of fetal antigen genotyping could significantly improve both clinical management and equitable access to care by minimizing the need for paternal or diagnostic testing.²⁴

There are four licensed sources of Rhlg in the US, including RhoGAM. In December 2023, the FDA, American Society of Health System Pharmacists (ASHP), and Association for the Advancement of Blood & Biotherapies (AABB) each independently reported a shortage of an active ingredient for RhoGAM, causing a reduction of supply. The shortage was expected to last throughout 2024 with an impact not only on RhoGAM but also with downstream effects on the availability of alternative sources.²⁵ In response, ACOG issued a Practice Advisory on how best to prioritize and conserve Rhlg supplies if the shortage were to persist.²⁶ Among these recommendations, ACOG stated that while, based on cost-effectiveness analyses, their current guidance does not recommend routine use of cfDNA screening to determine fetal RhD status, its use is a reasonable option to prioritize Rhlg and conserve its supply. An updated ACOG Clinical Practice Update regarding management of alloimmunization in pregnancy was published in August 2024.²⁷ Its intent was to clarify guidance on paternal genotyping and to provide new recommendations regarding the role of cfDNA for fetal red blood cell genotyping in at-risk pregnancies. Three clinical scenarios were outlined: (1) Partner testing for those pregnant patients confirmed to already be RhD-sensitized, assuming that non-paternity has been refuted; (2) Fetal genotyping when the biological father is either confirmed to be heterozygous (i.e., Dd) or is unknown, either by diagnostic testing (amniocentesis) or cfDNA if amniocentesis is declined; and, (3) Determination of both paternal and fetal genotypes in pregnant patients who are alloimmunized to a non-RhD allele where cfDNA could be considered for those who decline amniocentesis.

References

1. Knob AL. Principles of genetic testing and genetic counseling for renal clinicians. *Semin Nephrol.* 2010;30(4):431-7.
2. Pollard S, Sun S, Regier DA. Balancing uncertainty with patient autonomy in precision medicine. *Nat Rev Genet.* 2019;20(5):251-2.
3. Borno HT, Rider JR, Gunn CM. The Ethics of Delivering Precision Medicine-Pretest Counseling and Somatic Genomic Testing. *JAMA Oncol.* 2020;6(6):815-6.
4. Carlson LM, Vora NL. Prenatal Diagnosis: Screening and Diagnostic Tools. *Obstet Gynecol Clin North Am.* 2017;44(2):245-56.
5. Bianchi DW, Chiu RWK. Sequencing of Circulating Cell-free DNA during Pregnancy. *N Engl J Med.* 2018;379(5):464-73.
6. Allyse MA, Wick MJ. Noninvasive Prenatal Genetic Screening Using Cell-free DNA. *Jama.* 2018;320(6):591-2.
7. Liu P, Vossaert L. Emerging technologies for prenatal diagnosis: The application of whole genome and RNA sequencing. *Prenat Diagn.* 2022;42(6):686-96.
8. Palomaki GE, Chiu RWK, Pertile MD, et al. International Society for Prenatal Diagnosis Position Statement: cell free (cf)DNA screening for Down syndrome in multiple pregnancies. *Prenat Diagn.* 2021;41(10):1222-32.
9. Rose NC, Barrie ES, Malinowski J, et al. Systematic evidence-based review: The application of noninvasive prenatal screening using cell-free DNA in general-risk pregnancies. *Genet Med.* 2022;24(7):1379-91.
10. Shear MA, Swanson K, Garg R, et al. A systematic review and meta-analysis of cell-free DNA testing for detection of fetal sex chromosome aneuploidy. *Prenat Diagn.* 2023;43(2):133-43.
11. American College of Obstetricians and Gynecologists (ACOG). Screening for Fetal Chromosomal Abnormalities: ACOG Practice Bulletin, Number 226. *Obstet Gynecol.* 2020;136(4):e48-e69.

12. Dungan JS, Klugman S, Darilek S, et al. Noninvasive prenatal screening (NIPS) for fetal chromosome abnormalities in a general-risk population: An evidence-based clinical guideline of the American College of Medical Genetics and Genomics (ACMG). *Genetics in Medicine*. 2023;25(8):100874.
13. Hui L, Ellis K, Mayen D, et al. Position statement from the International Society for Prenatal Diagnosis on the use of non-invasive prenatal testing for the detection of fetal chromosomal conditions in singleton pregnancies. *Prenat Diagn*. 2023;43(7):814-28.
14. US Food & Drug Administration. Genetic non-invasive prenatal screening tests may have false results: fda safety communication. 2022.
15. Gregg AR, Skotko BG, Benkendorf JL, et al. Noninvasive prenatal screening for fetal aneuploidy, 2016 update: a position statement of the American College of Medical Genetics and Genomics. *Genet Med*. 2016;18(10):1056-65.
16. Gregg AR, Rajkovic A. Cell-Free DNA Screening During Pregnancy. *Jama*. 2019;321(3):308-9.
17. Faieta M, Falcone R, Duca S, et al. Test performance and clinical utility of expanded non-invasive prenatal test: Experience on 71,883 unselected routine cases from one single center. *Prenat Diagn*. 2024;44(8):936-45.
18. Hammer C, Pierson S, Acevedo A, et al. High positive predictive value 22q11.2 microdeletion screening by prenatal cell-free DNA testing that incorporates fetal fraction amplification. *Prenat Diagn*. 2024;44(8):925-35.
19. Kong L, Li S, Zhao Z, et al. Exploring factors impacting haplotype-based noninvasive prenatal diagnosis for single-gene recessive disorders. *Clin Genet*. 2024;105(1):52-61.
20. Dean L. Chapter 2: Blood Group Antigens are Surface Markers on the Red Blood Cell Membrane. *Blood Groups and Red Cell Antigens*. Vol. Bethesda (MD): National Center for Biotechnology Information; 2005.
21. Moise KJ, Jr., Abels EA. Management of Red Cell Alloimmunization in Pregnancy. *Obstet Gynecol*. 2024;144(4):465-80.
22. Mari G, Norton ME, Stone J, et al. Society for Maternal-Fetal Medicine (SMFM) Clinical Guideline #8: The fetus at risk for anemia—diagnosis and management. *American Journal of Obstetrics and Gynecology*. 2015;212(6):697-710.
23. Alford B, Landry BP, Hou S, et al. Validation of a non-invasive prenatal test for fetal RhD, C, c, E, K and Fy(a) antigens. *Sci Rep*. 2023;13(1):12786.
24. Rego S, Ashimi Balogun O, Emanuel K, et al. Cell-Free DNA Analysis for the Determination of Fetal Red Blood Cell Antigen Genotype in Individuals With Alloimmunized Pregnancies. *Obstet Gynecol*. 2024;144(4):436-43.
25. FDA USFDA. CBER-Regulated Products: Current Shortages 2024 [12/9/2024]. Available from: <https://www.fda.gov/vaccines-blood-biologics/safety-availability-biologics/cber-regulated-products-current-shortages>.
26. ACOG. Rho(D) Immune Globulin Shortages 2024 [updated July 9, 2024 Accessed October 31, 2024]. Available from: <https://www.acog.org/clinical/clinical-guidance/practice-advisory/articles/2024/03/rhod-immune-globulin-shortages>.
27. ACOG. ACOG Clinical Practice Update: Paternal and Fetal Genotyping in the Management of Alloimmunization in Pregnancy. *Obstetrics & Gynecology*. 2024;144(2):e47-e9.

Codes

The following code list is not meant to be all-inclusive. Authorization requirements will vary by health plan. Please consult the applicable health plan for guidance on specific procedure codes.

Specific CPT codes for services should be used when available. Nonspecific or not otherwise classified codes may be subject to additional documentation requirements and review.

CPT/HCPCS

CPT® (Current Procedural Terminology) is a registered trademark of the American Medical Association (AMA). CPT® five-digit codes, nomenclature and other data are copyright by the American Medical Association. All Rights Reserved. AMA does not directly or indirectly practice medicine or dispense medical services. AMA assumes no liability for the data contained herein or not contained herein.

May Be Medically Necessary When Criteria are Met

| Code | May Be Medically Necessary When Criteria are Met |
|-------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 81403 | Molecular pathology procedure, Level 4 (eg, analysis of single exon by DNA sequence analysis, analysis of >10 amplicons using multiplex PCR in 2 or more independent reactions, mutation scanning or duplication/deletion variants of 2-5 exons) |
| 81420 | Fetal chromosomal aneuploidy (eg, trisomy 21, monosomy X) genomic sequence analysis panel, circulating cell-free fetal DNA in maternal blood, must include analysis of chromosomes 13, 18, and 21 |
| 81479 | Unlisted molecular pathology procedure |
| 81507 | Fetal aneuploidy (trisomy 21, 18, and 13) DNA sequence analysis of selected regions using maternal plasma, algorithm reported as a risk score for each trisomy |

| Code | May Be Medically Necessary When Criteria are Met |
|-------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 81599 | Unlisted multianalyte assay with algorithmic analysis [when specified as cell-free fetal DNA-based prenatal testing involving multianalyte assays and an algorithmic analysis for fetal aneuploidy] |
| 0327U | Fetal aneuploidy (trisomy 13, 18, and 21), DNA sequence analysis of selected regions using maternal plasma, algorithm reported as a risk score for each trisomy, includes sex reporting, if performed |

Not Medically Necessary

| Code | Not Medically Necessary |
|-------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 81422 | Fetal chromosomal microdeletion(s) genomic sequence analysis (eg, DiGeorge syndrome, Cri-du-chat syndrome), circulating cell-free fetal DNA in maternal blood. |
| 0060U | Twin zygosity, genomic targeted sequence analysis of chromosome 2, using circulating cell-free fetal DNA in maternal blood |
| 0341U | Fetal aneuploidy DNA sequencing comparative analysis, fetal DNA from products of conception, reported as normal (euploidy), monosomy, trisomy, or partial deletion/duplication, mosaicism, and segmental aneuploid |
| 0488U | Obstetrics (fetal antigen noninvasive prenatal test), cell-free DNA sequence analysis for detection of fetal presence or absence of 1 or more of the Rh, C, c, D, E, Duffy (Fya), or Kell (K) antigen in alloimmunized pregnancies, reported as selected antigen(s) detected or not detected (Do not report 0488U in conjunction with 0632U) |
| 0489U | Obstetrics (single-gene noninvasive prenatal test), cell-free DNA sequence analysis of 1 or more targets (eg, CFTR, SMN1, HBB, HBA1, HBA2) to identify paternally inherited pathogenic variants, and relative mutation-dosage analysis based on molecular counts to determine fetal inheritance of maternal mutation, algorithm reported as a fetal risk score for the condition (eg, cystic fibrosis, spinal muscular atrophy, beta hemoglobinopathies [including sickle cell disease], alpha thalassemia) |
| 0494U | Red blood cell antigen (fetal RhD gene analysis), next-generation sequencing of circulating cell-free DNA (cfDNA) of blood in pregnant individuals known to be RhD negative, reported as positive or negative |
| 0536U | Red blood cell antigen (fetal RhD), PCR analysis of exon 4 of RHD gene and housekeeping control gene GAPDH from whole blood in pregnant individuals at 10+ weeks gestation known to be RhD negative, reported as fetal RhD status |
| 0632U | Red blood cell antigen (fetal RhD gene analysis), multiplex polymerase chain reaction (PCR) and next-generation sequencing (NGS) of circulating cell-free DNA (cfDNA), plasma from pregnant individuals known to be RhD negative, reported as detected or not detected (Do not report 0632U in conjunction with 0488U) |
| 0633U | Obstetrics (single-gene noninvasive prenatal test), cell-free DNA (cfDNA), next-generation sequencing (NGS) analysis of 1 or more targets (eg, CFTR, SMN1, HBB, HBA1, HBA2) to identify paternally inherited pathogenic variants and to determine fetal inheritance of maternal mutation, using maternal blood sample, algorithm reported as a fetal risk score |

ICD-10 Diagnosis

Refer to the ICD-10 CM manual

History

| Status | Review Date | Effective Date | Action |
|-----------------------------|-------------|----------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Updated codes 07/01/2026 | n/a | Unchanged | CPT code update: added new 0632U, 0633U (NMN). |
| Revised | 01/30/2025 | 09/20/2025 | Independent Multispecialty Physician Panel (IMPP) review. Clarified that cfDNA screening for fetal red blood cell antigens is considered not medically necessary when screening for single genes. Added references. Added CPT code 81403 (MNWCM). |
| Updated codes 04/01/2025 | n/a | Unchanged | Added CPT code 0536U (NMN). |
| Revised | 04/15/2024 | 11/17/2024 | IMPP review. Changed prenatal testing to prenatal screening throughout guideline. Expanded criteria to include follow-up screening for abnormal maternal serum screen results in viable singleton/twin pregnancies when diagnostic testing is declined and screening for pregnancies with multiple anomalies when diagnostic testing is not possible. Added references. |
| Updated codes 10/01/2024 | n/a | Unchanged | Added CPT codes 0488U, 0489U, 0494U (NMN). |

| Status | Review Date | Effective Date | Action |
|---------|-------------|----------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Revised | 07/18/2023 | 03/17/2024 | IMPP review. Clarified the required components of genetic counseling. For viable singleton or twin pregnancy, clarified sex prediction for pregnancies at risk for an X-linked disorder. Updated references. Split codes into those considered medically necessary when criteria are met (MNWCM) and not MN. Added CPT 0341U (NMN). Added required language to General Clinical Guideline per new Medicare regulations. |
| Updated | n/a | 10/01/2023 | Added CPT code 81599. |
| Created | 09/21/2022 | 02/12/2023 | IMPP review. Original effective date. |